Abu Dhabi (WAM)
“M42”, the global company that seeks to reshape the future of health using the latest technologies, based in Abu Dhabi, has signed a cooperation agreement with “AstraZeneca”, a global company specialized in biopharmaceutical industries, to develop preventive health care solutions and the next generation of precision medicine for breast cancer.
As AstraZeneca’s preferred partner in the field of clinical genomics in the Middle East, M42 will sequence the inherited genes that cause breast cancer. With the aim of formulating personalized care plans and preventive strategies that meet the needs of each individual patient. This initiative represents an indication of the advanced capabilities of “M42” in developing genetic sequencing supported by multiple “omics” technologies in the field of tumor diagnosis, which is a relatively new field that holds tremendous potential for improving therapeutic outcomes for patients.
By supporting the genetic sequencing of cancer, M42 will lead efforts to identify the specific genes in each patient that make them susceptible to cancer, which enhances the ability to discover preventive measures in the early stages, or even before the disease itself appears. To do this, “M42”, in partnership with “AstraZeneca”, offers one of the first diagnostic programs of its kind in the Arabian Gulf region, in addition to the possibility of benefiting from the results to improve personalized drug interventions for each individual patient.
Dr. Fahd Al Marzouqi, Executive Vice President of Group Operations at M42, said: “M42 places the latest innovations at the heart of its work methodology, and is committed to anticipating the future of health while providing the next generation of preventive and precision medicine solutions. This innovative program, supported by pioneering Omex technologies, aims to provide personalized treatments and interventions for cancer, which directly contributes to improving the therapeutic outcomes for patients, and paves the way towards consolidating the foundations of the preventive medicine methodology, which is consistent with our mission of supporting all individuals, not just patients, and focusing on prevention. “It is not just treatment, and our partnership with AstraZeneca seeks to lay the foundations for a future based on precision medicine in which addressing health challenges becomes easier and more efficient.”
For his part, Peter Raouf, Director of the Oncology Department at AstraZeneca for the Gulf Cooperation Council region, said: “This cooperation with M42 represents an ambitious step towards achieving our commitment to developing precision personalized medicine in the field of cancer research, and we are pleased to support the efforts directed to perpetuate the model of preventive cancer care by benefiting from “From M42’s advanced expertise in the field of genomics, continuing to improve therapeutic outcomes for patients is at the top of our list of priorities in a way that benefits people and society as a whole.”
The sequencing process is taking place within the M42 Omics Center of Excellence, one of the largest multi-omics research facilities in the world, which focuses specifically on enriching advanced genomics knowledge, and plays an active role in implementing one of the largest population genomics initiatives in the world. Represented by the Emirati Genome Programme.
Within the framework of this program, the Department of Health Abu Dhabi published guidelines on germline mutation testing to assess predisposition to breast and ovarian cancer, to enhance precision medicine practices in the emirate and design treatment plans based on the genetic makeup of patients. For the purpose of the study, the researchers are directing their focus on patients from the UAE, Kuwait, the Sultanate of Oman, Bahrain and Qatar, to enrich genomic knowledge related to non-Western population groups whose representation rates in clinical research are practically low. Under the agreement, Cleveland Clinic Abu Dhabi will be the first hospital to take genomic data samples from patients who have expressed their consent to do so, and it is part of the “M42” network.
#Cooperation #agreement #M42 #AstraZeneca